GlassScriptPhysician profile
Michael Edward Haughton
NPI 1316266208
$3,312.56
in general payments reported to CMS, 2019-2025
32 companies · $59.53 in 2025
The $59.53 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $869 · 2021: $457 · 2022: $312 · 2023: $39.41 · 2024: $483 · 2025: $59.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.97 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,164.16 | 2019-2021 | |
| Amgen INC. | $546.82 | 2020-2024 | Imdelltra (Amg 757) |
| Incyte Corporation | $171.27 | 2019-2022 | |
| Genentech USA, INC. | $132.03 | 2019-2021 | |
| Biocompatibles, INC. | $114.24 | 2019 | |
| Merck Sharp & Dohme LLC | $112.53 | 2019-2022 | |
| Janssen Biotech, INC. | $100.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.27 | 2019-2025 | Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $89.24 | 2019-2022 | |
| Genzyme Corporation | $86.09 | 2020-2021 | |
| Celgene Corporation | $76.69 | 2019-2025 | Pomalyst, Opdivo |
| Pfizer INC. | $68.82 | 2019-2022 | |
| Eisai INC. | $59.32 | 2019-2021 | |
| Lilly USA, LLC | $57.03 | 2019-2022 | |
| Gilead Sciences, INC. | $52.14 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.35 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.36 | 2020-2022 | |
| Glaxosmithkline, LLC. | $35.66 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $31.02 | 2021 | |
| Karyopharm Therapeutics INC. | $26.08 | 2020 | |
| Taiho Oncology, INC. | $23.51 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.52 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Morphosys, US INC. | $20.91 | 2021 | |
| Kite Pharma, INC. | $18.27 | 2022 | |
| Abbvie INC. | $17.84 | 2025 | |
| Kyowa Kirin, INC. | $17.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.00 | 2019 | |
| Epizyme, INC. | $15.55 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.32 | 2020 | |
| Exelixis INC. | $12.81 | 2019 | |
| Coherus Oncology, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Haughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.